IDEAYA Biosciences, Inc. (IDYA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs.
Is IDEAYA Biosciences, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, IDEAYA Biosciences, Inc. (IDYA) trades at $31.96 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: IDEAYA Biosciences, Inc.
Market cap $3B · 52 weeks $28 – $42 (25 % below the high) · P/E no earnings · Dividend none · Next earnings November 9, 2026 · expected EPS $-1.18 · Closing price, Oct 30 · accounts published Aug 4.
- Valuation: P/Sales 11.0× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 3 of 4 pass
- Market cap / Cash 4.4×, fails.
- Cash Runway 108 meses, passes.
- Total Debt 0.0×, passes.
- R&D / Market cap 11.1 %, passes.
- Annual cash burn $0.80, info.
Against its peers (reference peers) — IDEAYA Biosciences, Inc.: P/E —; EV/EBITDA —; ROIC -17.7 %; $3.1B. Nurix Therapeutics, Inc. (P/E 11.6×; EV/EBITDA 7.0×; ROIC 25.9 %; $2.9B), Telix Pharmaceuticals Limited (P/E 94.9×; EV/EBITDA 114×; ROIC -0.6 %; $3.1B), Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B).
Profitability
| Return on Equity | -16.47% |
| Return on Invested Capital | -17.66% |
| Return on Assets | -13.36% |
| Gross Margin | 100.00% |
| Operating Margin | -92.66% |
| Net Margin | -74.75% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 10.45 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 20.70 |
Price Performance
| 1 month | -14.45% |
| 3 months | -9.72% |
| Year-to-date | -7.55% |
| 1 year | +0.31% |
| 3 years | +7.72% |
| 5 years | +41.42% |
Related companies: RVMD · COGT · ERAS · TNGX · NRIX
Explore sector: Healthcare · Biotechnology
More sections of IDYA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks